Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Amit Kumar, chairman and CEO, will present at RedChip's virtual Biotech Resurgence conference on April 16, 2026 at 3:30 pm ET.

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Amit Kumar, chairman and CEO, will present at RedChip's virtual Biotech Resurgence conference on April 16, 2026 at 3:30 pm ET.

The presentation will review the company, its Phase 1 breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants, and ovarian CAR-T therapy lira-cel showing positive survival data in an ongoing Phase 1 trial. The session includes a live Q&A for investors and registration details.

Argus Apr 9 session

+0.37% close to close Open Argus

Details

News Market Reaction – ANIX

On Apr 9, the day this news came out, ANIX closed 0.37% above the previous close.

Data tracked by StockTitan Argus for the Apr 9 session.

Market Context

This announcement centers on ANIX’s participation in a April 16, 2026 RedChip virtual conference, sp...

Analysis

This announcement centers on ANIX’s participation in a April 16, 2026 RedChip virtual conference, spotlighting its breast cancer vaccine, which generated protocol-defined immune responses in 74% of Phase 1 participants, and its ovarian cancer CAR‑T program with positive survival data in Phase 1. Recent history shows frequent investor outreach around these programs. Investors may watch for deeper efficacy and safety data in future updates and any financing steps under the existing Form S-3 shelf.

Key Figures

Immune response rate: 74% of participants Trial phase: Phase 1 Trial phase: Phase 1 +2 more

Immune response rate

74% of participants

Phase 1 breast cancer vaccine trial

Trial phase

Phase 1

Breast cancer vaccine clinical trial

Trial phase

Phase 1

Ovarian cancer CAR-T (lira-cel) trial

Conference date

April 16, 2026

RedChip Biotech Resurgence virtual investor conference

Presentation time

3:30 pm ET

ANIX session at RedChip virtual conference

Historical Context

5 past events · Latest: Apr 07

5 events

1. Apr 07

   Investor conference

   24h Move

   +3.9%

   Water Tower investor conference featuring strategy and recent clinical highlights.

2. Apr 06

   Media interview

   24h Move

   +1.6%

   CEO interview discussing advancing immunotherapy pipeline and trial progress.

3. Apr 01

   Clinical trial update

   24h Move

   +5.4%

   Positive final Phase 1 breast cancer vaccine results and move toward Phase 2.

4. Mar 30

   Conference presentation

   24h Move

   -2.0%

   Announcement of lira-cel Phase 1 data presentation at oncology meeting.

5. Mar 12

   Podcast appearance

   24h Move

   -2.7%

   Podcast featuring positive trial data and discussion of plans and finances.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car-t therapy, phase 1, clinical trial

3 terms

car-t therapy medical

"Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data..."

CAR-T therapy is a type of medical treatment that uses a patient's own immune cells, specially modified to better recognize and attack cancer cells. For investors, it represents a significant advancement in cancer care, with the potential to transform treatment options and generate substantial demand, making companies involved in its development and production potentially valuable in the healthcare industry.

phase 1 medical

"participants in Phase 1 clinical trial...ongoing Phase 1 clincal trial"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

clinical trial medical

"participants in Phase 1 clinical trial...ongoing Phase 1 clincal trial"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Breast cancer vaccine met primary endpoints and generated protocol-defined immune
responses in 74% of participants in Phase 1 clinical trial

Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1
clincal trial

SAN JOSE, Calif., April 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Anixa's Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today's Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.

The presentation will cover several topics, including an overview of the Company and its business model, the Company's breast cancer vaccine meeting primary endpoints and generating protocol-defined immune responses in 74% of participants in its Phase 1 clinical trial, and the Company's ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in its ongoing Phase 1 clinical trial.

RedChip's virtual investor conference brings investors direct access to publicly traded companies advancing the future of healthcare across biopharma, medtech, diagnostics, and digital health. Throughout this full-day virtual event, company executives will present their business models, pipeline strategies, clinical and commercial milestones, and competitive positioning within an evolving healthcare landscape. Each session will include a live Q&A, giving investors the opportunity to engage directly with leadership teams.

Registration to attend this virtual investor conference may be completed at: Event Registration.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-redchips-biotech-resurgence-platforms-and-pipelines-of-todays-innovators-conference-on-april-16-2026-302737590.html

SOURCE Anixa Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Anixa (ANIX) present at the RedChip Biotech Resurgence conference?

Anixa will present on April 16, 2026 at 3:30 pm ET. According to the company, Dr. Amit Kumar will cover the corporate overview, the Phase 1 breast cancer vaccine results, and lira-cel ovarian CAR-T survival data during the virtual session with live Q&A.

What Phase 1 breast cancer vaccine results did Anixa (ANIX) report?

The vaccine met primary endpoints and showed immune responses in 74% of participants in Phase 1. According to the company, this metric reflects protocol-defined immune responses observed during the Phase 1 clinical trial reported in the announcement.

What did Anixa (ANIX) say about its ovarian CAR-T therapy lira-cel?

Anixa reported that lira-cel is exhibiting positive survival data in an ongoing Phase 1 trial. According to the company, Dr. Amit Kumar will discuss these survival outcomes and the therapy's clinical progress at the April 16 presentation.

How can investors attend Anixa's (ANIX) RedChip presentation and participate in Q&A?

Investors can register for the virtual conference via the event registration link to attend and join live Q&A. According to the company, the full-day RedChip event provides direct investor access and each session includes a live question-and-answer period with executives.

What topics will Anixa (ANIX) cover during the April 16 presentation?

The presentation will cover company overview, business model, Phase 1 breast vaccine results, and lira-cel ovarian CAR-T survival data. According to the company, Dr. Amit Kumar will also address pipeline strategy, clinical milestones, and take live investor questions.